Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer

Motowo Mizuno, Masahiro Nakagawa, Tokurou Uesu, Hiroshi Inoue, Tomoki Inaba, Toru Ueki, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Takao Tsuji

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background & Aims: Colorectal cancers have an increased expression of decay-accelerating factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) (P <0.05), patients with upper gastrointestinal cancer (0-3.1 ng/g; median, 0 ng/g) (P <0.05), and subjects without gastrointestinal disease (0-3.4 ng/g; median, 0 ng/g) (P <0.01). Resection of colorectal cancers caused a marked decrease in stool DAF concentrations. The stool DAF test was positive in a substantial portion of patients with colorectal cancer whose tumors were small (

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalGastroenterology
Volume109
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

CD55 Antigens
Colorectal Neoplasms
Gastrointestinal Neoplasms
Gastrointestinal Diseases
Adenomatous Polyps
Immunoassay
Adenoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Mizuno, M., Nakagawa, M., Uesu, T., Inoue, H., Inaba, T., Ueki, T., ... Tsuji, T. (1995). Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. Gastroenterology, 109(3), 826-831. https://doi.org/10.1016/0016-5085(95)90390-9

Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. / Mizuno, Motowo; Nakagawa, Masahiro; Uesu, Tokurou; Inoue, Hiroshi; Inaba, Tomoki; Ueki, Toru; Nasu, Junichirou; Okada, Hiroyuki; Fujita, Teizo; Tsuji, Takao.

In: Gastroenterology, Vol. 109, No. 3, 1995, p. 826-831.

Research output: Contribution to journalArticle

Mizuno, M, Nakagawa, M, Uesu, T, Inoue, H, Inaba, T, Ueki, T, Nasu, J, Okada, H, Fujita, T & Tsuji, T 1995, 'Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer', Gastroenterology, vol. 109, no. 3, pp. 826-831. https://doi.org/10.1016/0016-5085(95)90390-9
Mizuno, Motowo ; Nakagawa, Masahiro ; Uesu, Tokurou ; Inoue, Hiroshi ; Inaba, Tomoki ; Ueki, Toru ; Nasu, Junichirou ; Okada, Hiroyuki ; Fujita, Teizo ; Tsuji, Takao. / Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. In: Gastroenterology. 1995 ; Vol. 109, No. 3. pp. 826-831.
@article{9c79db2828854bcc96e3412bd8ff7e81,
title = "Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer",
abstract = "Background & Aims: Colorectal cancers have an increased expression of decay-accelerating factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) (P <0.05), patients with upper gastrointestinal cancer (0-3.1 ng/g; median, 0 ng/g) (P <0.05), and subjects without gastrointestinal disease (0-3.4 ng/g; median, 0 ng/g) (P <0.01). Resection of colorectal cancers caused a marked decrease in stool DAF concentrations. The stool DAF test was positive in a substantial portion of patients with colorectal cancer whose tumors were small (",
author = "Motowo Mizuno and Masahiro Nakagawa and Tokurou Uesu and Hiroshi Inoue and Tomoki Inaba and Toru Ueki and Junichirou Nasu and Hiroyuki Okada and Teizo Fujita and Takao Tsuji",
year = "1995",
doi = "10.1016/0016-5085(95)90390-9",
language = "English",
volume = "109",
pages = "826--831",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer

AU - Mizuno, Motowo

AU - Nakagawa, Masahiro

AU - Uesu, Tokurou

AU - Inoue, Hiroshi

AU - Inaba, Tomoki

AU - Ueki, Toru

AU - Nasu, Junichirou

AU - Okada, Hiroyuki

AU - Fujita, Teizo

AU - Tsuji, Takao

PY - 1995

Y1 - 1995

N2 - Background & Aims: Colorectal cancers have an increased expression of decay-accelerating factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) (P <0.05), patients with upper gastrointestinal cancer (0-3.1 ng/g; median, 0 ng/g) (P <0.05), and subjects without gastrointestinal disease (0-3.4 ng/g; median, 0 ng/g) (P <0.01). Resection of colorectal cancers caused a marked decrease in stool DAF concentrations. The stool DAF test was positive in a substantial portion of patients with colorectal cancer whose tumors were small (

AB - Background & Aims: Colorectal cancers have an increased expression of decay-accelerating factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) (P <0.05), patients with upper gastrointestinal cancer (0-3.1 ng/g; median, 0 ng/g) (P <0.05), and subjects without gastrointestinal disease (0-3.4 ng/g; median, 0 ng/g) (P <0.01). Resection of colorectal cancers caused a marked decrease in stool DAF concentrations. The stool DAF test was positive in a substantial portion of patients with colorectal cancer whose tumors were small (

UR - http://www.scopus.com/inward/record.url?scp=0029156718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029156718&partnerID=8YFLogxK

U2 - 10.1016/0016-5085(95)90390-9

DO - 10.1016/0016-5085(95)90390-9

M3 - Article

C2 - 7544751

AN - SCOPUS:0029156718

VL - 109

SP - 826

EP - 831

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -